---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-006302"
form_type: "8-K"
ticker: "RCKT"
cik: "0001281895"
company_name: "ROCKET PHARMACEUTICALS, INC."
filed_at: "2025-02-27T23:59:59+00:00"
generated_at: "2026-05-26T01:09:15.368963+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Rocket Pharma FY2024 net loss $258.7M ($2.73/sh); cash $372.3M; RP-A501 Phase 2 ongoing

## Summary
- Net loss $258.7M ($2.73/sh) for FY2024 vs $245.6M ($2.92/sh) in FY2023.
- Cash, equivalents and investments $372.3M at Dec 31, 2024; runway into Q3 2026.
- Raised $182.5M net via Dec 2024 offering of 15.2M shares at $12.50/sh.
- RP-A501 Phase 2 pivotal dosing ongoing; NEJM publication shows efficacy up to 5 years.
- RP-A601 low dose cohort fully enrolled; initial data expected H1 2025. BAG3-DCM IND on track H1 2025.

## SEC filing metadata
- accession: 0001140361-25-006302
- form_type: 8-K
- ticker: RCKT
- cik: 0001281895
- company_name: ROCKET PHARMACEUTICALS, INC.
- filed_at: 2025-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1281895/000114036125006302/0001140361-25-006302-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1281895/000114036125006302/ef20044486_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-006302
- JSON: https://secwatch.observer/filing/0001140361-25-006302.json
- Plain text: https://secwatch.observer/filing/0001140361-25-006302.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.